isovaleramide

Isovaleramide (NPS 1776) is a neutral aliphatic amide and a small molecule compound originally discovered by NPS Pharmaceuticals. It has demonstrated broad anticonvulsant activity in multiple animal models of seizures, with a pharmacological profile similar to valproic acid. The precise mechanism of action remains unclear; it does not appear to bind directly to central nervous system receptor centers but shows efficacy in preclinical seizure models. Isovaleramide was investigated for the acute treatment of migraine pain and associated symptoms, as well as for potential use in neurological disorders such as epilepsy and other seizure-related conditions[1][7][9]. Clinical studies have shown that while it was safe, its efficacy in acute migraine treatment did not meet primary endpoints due to high placebo response rates[5].

Other names

3-methylbutanamideisovaleramide